AVTX (Avalo Therapeutics) Retained Earnings: $-468.15 Mil (As of Mar. 2026)


AVTX Avalo Therapeutics Inc AVTX
23 GF Score
Price $19.18
GF Value $0.03
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Avalo Therapeutics Retained Earnings?

Avalo Therapeutics AVTX -3.71% 23 Retained Earnings is $-468.15 Mil as of Mar. 2026. GuruFocus rates AVTX with a GF Score™ of 23/100 and a GF Value™ of $0.03 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Avalo Therapeutics's retained earnings for the quarter that ended in Mar. 2026 was $-468.15 Mil.

Avalo Therapeutics's quarterly retained earnings declined from Sep. 2025 ($-434.80 Mil) to Dec. 2025 ($-448.52 Mil) and declined from Dec. 2025 ($-448.52 Mil) to Mar. 2026 ($-468.15 Mil).

Avalo Therapeutics's annual retained earnings declined from Dec. 2023 ($-335.13 Mil) to Dec. 2024 ($-370.26 Mil) and declined from Dec. 2024 ($-370.26 Mil) to Dec. 2025 ($-448.52 Mil).


Avalo Therapeutics  (NAS:AVTX) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Avalo Therapeutics Retained Earnings Historical Data

* Premium members only.

The historical data trend for Avalo Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalo Therapeutics Retained Earnings Chart

Avalo Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -262.17 -303.82 -335.13 -370.26 -448.52

Avalo Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -383.41 -404.18 -434.80 -448.52 -468.15
AVTX
23GF Score
Avalo Therapeutics Inc AVTX
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalo Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-468.15 Mil mean?
Avalo Therapeutics (AVTX) has a Retained Earnings of $-468.15 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Avalo Therapeutics and its competitors.
Is Avalo Therapeutics' Retained Earnings too high?
Avalo Therapeutics' current Retained Earnings is $-468.15 Mil. Overall, Avalo Therapeutics has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avalo Therapeutics' Retained Earnings compare to SANA and ANRO?
Avalo Therapeutics' Retained Earnings of $-468.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Avalo Therapeutics and its competitors. Avalo Therapeutics's current Retained Earnings is $-468.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Avalo Therapeutics (AVTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.03, compared to a current price of $19.18 — trading 63833.3% above its estimated fair value. The current Retained Earnings is $-468.15 Mil. Avalo Therapeutics' overall GF Score™ is 23/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Avalo Therapeutics (AVTX), the current Retained Earnings is $-468.15 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Avalo Therapeutics (AVTX) Overvalued in 2026?

Based on GuruFocus' analysis, Avalo Therapeutics stock appears to be overvalued. The current stock price of $19.18 is trading 63833.3% above its estimated GF Value™ of $0.03. GuruFocus considers Avalo Therapeutics to be Significantly Overvalued.

Key valuation signals for AVTX:

  • Retained Earnings: $-468.15 Mil
  • GF Value™: $0.03 vs. price of $19.18 (63833.3% above fair value)
  • GF Score™: 23/100 with 8 warning signs

No single metric tells the full story. See the AVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Avalo Therapeutics Business Description

Other Exchanges C6K0:Germany
Address 1500 Liberty Ridge Drive, Suite 321, Wayne, PA, USA, 19087
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
23GF Score

Get the complete analysis for AVTX

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.18
Price
$0.03
GF Value